| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Quarterly results |
| 10/05/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/05/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/25/2023 |
4
| Palmer Pamela P (Chief Medical Officer) has filed a Form 4 on ACELRX PHARMACEUTICALS INC|
Txns:
| Sold 9,514 shares
@ $1.17, valued at
$11.1k
Sold 7,442 shares
@ $1.089, valued at
$8.1k
|
|
| 08/25/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/09/2023 |
424B7
| Form 424B7 - Prospectus [Rule 424(b)(7)]: |
| 08/02/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 07/21/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits... |
| 03/06/2023 |
4
| Dasu Badri N (Chief Engineering Officer) has filed a Form 4 on ACELRX PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 398 shares
@ $1.31, valued at
$521.4 |
|
| 03/06/2023 |
4
| Palmer Pamela P (Chief Medical Officer) has filed a Form 4 on ACELRX PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 570 shares
@ $1.31, valued at
$746.7 |
|
| 03/06/2023 |
4
| ASADORIAN RAFFI (CFO) has filed a Form 4 on ACELRX PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 510 shares
@ $1.31, valued at
$668.1 |
|
| 03/06/2023 |
4
| Angotti Vincent J. (CEO) has filed a Form 4 on ACELRX PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 1,703 shares
@ $1.31, valued at
$2.2k
|
|
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 10% stake in ACELRX PHARMACEUTICALS, INC. |
| 02/08/2023 |
4
| Dasu Badri N (Chief Engineering Officer) has filed a Form 4 on ACELRX PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 458 shares
@ $2.02, valued at
$925.2 |
|
| 02/08/2023 |
4
| ASADORIAN RAFFI (CFO) has filed a Form 4 on ACELRX PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 617 shares
@ $2.02, valued at
$1.2k
|
|
| 02/08/2023 |
4
| Palmer Pamela P (Chief Medical Officer) has filed a Form 4 on ACELRX PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 681 shares
@ $2.02, valued at
$1.4k
|
|
| 02/08/2023 |
4
| Angotti Vincent J. (CEO) has filed a Form 4 on ACELRX PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 1,982 shares
@ $2.02, valued at
$4k
|
|
| 12/29/2022 |
8-K
| Quarterly results |
| 12/28/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/05/2022 |
8-K
| Quarterly results |
| 11/23/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/22/2022 |
424B7
| Form 424B7 - Prospectus [Rule 424(b)(7)]: |
| 11/15/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
|